BeiGene
ONC
390.94
-8.76
-2.19%
BeiGene
US · ONC
#538 by market cap
Listed 2016
390.94
-8.76
-2.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 1 in the most recent period (2026/Q4).
- Total institutional ownership rose 1.3 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 78.72% +1.28pp
- Institutions
- 636 +1
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund43.98%
Public Company17.52%
Hedge Fund10.11%
VC/PE Fund4.44%
Individual/Insider4.19%
Sovereign Wealth Fund1.11%
Private Company1.05%
Government Pension Fund0.39%
Other17.12%
Top holders as of 2025-12-31
Amgen Inc.
16.58% · 18.94M sh
Capital Research
9.44% · 10.78M sh
Baker Bros. Advisors LP
7.77% · 8.87M sh
PRIMECAP Management Company
4.30% · 4.91M sh
Hillhouse Capital Management, Ltd.
3.71% · 4.24M sh
John Oyler
3.21% · 3.67M sh
BlackRock
2.89% · 3.30M sh
China Asset Management Co., Ltd.
2.63% · 3.00M sh
Vanguard Capital Management, LLC
2.37% · 2.71M sh
FMR
2.01% · 2.29M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 13 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Amgen Inc. | -- | 16.58% |
| John Oyler | Chairperson & CEO | 3.21% |
| Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | 0.63% |
| Wang Lai | President and Global Head of Research & Development | 0.15% |
| Xiaobin Wu | Former President | 0.05% |
| Felix Baker | Independent Non-Executive Director | 0.02% |
| Chan Lee | General Counsel, Senior VP & Corporate Secretary | 0.02% |
| Michael Goller | Former Independent Non-Executive Director | 0.02% |
| Ranjeev Krishana | Former Lead Independent Director | 0.02% |
| Julia A. Wang | Former CFO & Principal Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Other Disposition | -1,183 | -- |
| 2026-11-05 | Titus Ball | Vice President | Derivative Exercise and Sale | -1,559 | $159.03–406.34 |
| 2026-11-04 | Chan Lee | General Counsel, Senior VP & Corporate Secretary | Private Disposition | -1,115 | $400.00–402.00 |
| 2026-10-26 | Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Derivative Exercise and Sale | -31,028 | $36.90–366.22 |
| 2026-10-12 | Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Derivative Exercise and Sale | -31,027 | $36.90–353.24 |
| 2026-09-29 | Chan Lee | General Counsel, Senior VP & Corporate Secretary | Automatic Disposition | -1,115 | $375.00 |
| 2026-09-27 | Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Derivative Exercise and Sale | -31,028 | $36.90–367.23 |
| 2026-09-07 | Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Automatic Disposition | -7,260 | $345.38–348.01 |
| 2026-09-07 | Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Derivative Exercise and Sale | -31,027 | $36.90–351.25 |
| 2026-08-31 | Titus Ball | Vice President | Open Market Disposition | -132 | $355.86 |
| 2026-08-24 | Corazon Sanders | Former Independent Non-Executive Director | Intent to Sell (Form 144) | -2,075 | $380.00 |
| 2026-08-24 | Xiaobin Wu | Former President | Automatic Disposition | -280 | $380.00 |
| 2026-08-11 | John Oyler | Chairperson & CEO | Automatic Disposition | -240,810 | $350.00–367.00 |
| 2026-08-10 | Chan Lee | General Counsel, Senior VP & Corporate Secretary | Derivative Exercise and Sale | -2,666 | $159.03–360.00 |
| 2026-08-09 | John Oyler | Chairperson & CEO | Intent to Sell (Form 144) | -240,810 | $348.27 |
| 2026-08-02 | Aaron Rosenberg | Chief Financial Officer | Open Market Disposition | -1,157 | $312.72 |
| 2026-07-29 | Chan Lee | General Counsel, Senior VP & Corporate Secretary | Open Market Disposition | -1,044 | $323.69 |
| 2026-07-21 | Chan Lee | General Counsel, Senior VP & Corporate Secretary | Derivative Exercise and Sale | -1,669 | $159.03–325.00 |
| 2026-07-20 | John Oyler | Chairperson & CEO | Automatic Disposition | -75,723 | $310.08–320.06 |
| 2026-07-19 | John Oyler | Chairperson & CEO | Derivative Exercise and Sale | -33,990 | $119.96–318.30 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BeiGene discussion 0 comments